FarFaR - Pharmacy Repository
University of Belgrade, Faculty of Pharmacy
    • English
    • Српски
    • Српски (Serbia)
  • English 
    • English
    • Serbian (Cyrillic)
    • Serbian (Latin)
  • Login
View Item 
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
  •   FarFaR
  • Pharmacy
  • Radovi istraživača / Researchers’ publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Hormones as biotech-drugs: Human insulin and insulin analogues

Hormoni kao biotehnološki lekovi - humani insulin i analozi

Thumbnail
2010
1418.pdf (371.8Kb)
Authors
Savić, Snežana
Vuleta, Gordana
Savić, Miroslav
Article (Published version)
Metadata
Show full item record
Abstract
Biotech-drugs or biopharmaceuticals are proteins or nucleic acids, which have been produced by living organisms as a result of biotechnology. Three decades after the beginning steps, they make a third part of all new drugs appearing each year at the world market. The era of animal source insulins has passed away and human recombinant DNA insulin and insulin analogues, as biopharmaceutics of the first and second generations, respectively, are the cornerstone of the diabetes mellitus current therapy. All insulin preparations are divided into three groups: 1) short - and rapid-acting insulins; 2) intermediate-acting insulins and 3) long-acting insulins. Short-acting human insulins and rapid-acting analogous insulin lispro, aspart and glulisine are available in form of solution for injections. In order to achieve the intermediate duration of action, human insulin is co-crystallized with protamine (insulin isophane suspensions) or human insulins and rapid-acting analogues are prepared as mi...xtures of isophane insulin suspension and monomer soluble form in fixed-ratios (75/25, 70/30, 50/50). The currently available long-acting insulins are analogues insulin glargine and insulin detemir, whereas use of amorphous and crystalline insulin zinc suspensions (lente and ultralente insulins) for prolonged action is now very rare, because of insufficiently favorable pharmacokinetics. Similarly, inhalation administration of insulin, although introduced into clinical practice, did not show the expected benefits in comparison to the conventional parenteral use.

Biotehnološki lekovi ili biofarmaceutici su proteini ili nukleinske kiseline koje proizvode živi organizmi primenom biotehnoloških postupaka. Tri decenije nakon početnih koraka, oni čine trećinu svih novih lekova koji se svake godine pojave na tržištu u svetu. Era insulina životinjskog porekla je prošla i humani insulin dobijen rekombinantnom DNK tehnologijom i insulinski analozi, kao biotehnološki lekovi prve, odnosno druge generacije, čine osnovu savremene terapije dijabetes melitusa. Svi preparati insulina dele se u tri osnovne grupe: 1) kratko - i brzo-delujuće insuline; 2) srednje-delujuće insuline; 3) dugo-delujuće insuline. Kratko-delujući humani insulin i brzo-delujući analozi insulin lispro, insulin aspart i insulin glulizin prisutni su u obliku rastvora za injekcije. U cilju postizanja srednje dužine dejstva humani insulin se formuliše kao kokristalizat sa protaminom (insulin izofan suspenzija) ili se humani insulin i brzo-delujući analozi pripremaju kao mešavine insulin izof...an suspenzije i monomernog rastvornog oblika u određenim odnosima (75/25, 70/30, 50/50). Kao dugo-delujući insulini primenjuju se analozi insulin glargin i insulin detemir, dok se produženje dejstva stvaranjem amorfne ili kristalne insulin cink suspenzije (lente i ultralente insulin) sve manje koristi, zbog nedovoljno povoljne farmakokinetike. Slično, inhalaciona primena insulina, iako uvedena u kliničku praksu, nije pokazala očekivane prednosti u odnosu na konvencionalnu parenteralnu primenu.

Keywords:
human insulin / biopharmaceutics / insulin analogues / recombinant DNA technology / humani insulin / biotehnološki lekovi / analozi insulina / rekombinantna DNK tehnologija
Source:
Arhiv za farmaciju, 2010, 60, 2, 207-225
Publisher:
  • Savez farmaceutskih udruženja Srbije, Beograd

ISSN: 0004-1963

Scopus: 2-s2.0-77954197292
[ Google Scholar ]
1
Handle
https://hdl.handle.net/21.15107/rcub_farfar_1420
URI
https://farfar.pharmacy.bg.ac.rs/handle/123456789/1420
Collections
  • Radovi istraživača / Researchers’ publications
Institution/Community
Pharmacy
TY  - JOUR
AU  - Savić, Snežana
AU  - Vuleta, Gordana
AU  - Savić, Miroslav
PY  - 2010
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/1420
AB  - Biotech-drugs or biopharmaceuticals are proteins or nucleic acids, which have been produced by living organisms as a result of biotechnology. Three decades after the beginning steps, they make a third part of all new drugs appearing each year at the world market. The era of animal source insulins has passed away and human recombinant DNA insulin and insulin analogues, as biopharmaceutics of the first and second generations, respectively, are the cornerstone of the diabetes mellitus current therapy. All insulin preparations are divided into three groups: 1) short - and rapid-acting insulins; 2) intermediate-acting insulins and 3) long-acting insulins. Short-acting human insulins and rapid-acting analogous insulin lispro, aspart and glulisine are available in form of solution for injections. In order to achieve the intermediate duration of action, human insulin is co-crystallized with protamine (insulin isophane suspensions) or human insulins and rapid-acting analogues are prepared as mixtures of isophane insulin suspension and monomer soluble form in fixed-ratios (75/25, 70/30, 50/50). The currently available long-acting insulins are analogues insulin glargine and insulin detemir, whereas use of amorphous and crystalline insulin zinc suspensions (lente and ultralente insulins) for prolonged action is now very rare, because of insufficiently favorable pharmacokinetics. Similarly, inhalation administration of insulin, although introduced into clinical practice, did not show the expected benefits in comparison to the conventional parenteral use.
AB  - Biotehnološki lekovi ili biofarmaceutici su proteini ili nukleinske kiseline koje proizvode živi organizmi primenom biotehnoloških postupaka. Tri decenije nakon početnih koraka, oni čine trećinu svih novih lekova koji se svake godine pojave na tržištu u svetu. Era insulina životinjskog porekla je prošla i humani insulin dobijen rekombinantnom DNK tehnologijom i insulinski analozi, kao biotehnološki lekovi prve, odnosno druge generacije, čine osnovu savremene terapije dijabetes melitusa. Svi preparati insulina dele se u tri osnovne grupe: 1) kratko - i brzo-delujuće insuline; 2) srednje-delujuće insuline; 3) dugo-delujuće insuline. Kratko-delujući humani insulin i brzo-delujući analozi insulin lispro, insulin aspart i insulin glulizin prisutni su u obliku rastvora za injekcije. U cilju postizanja srednje dužine dejstva humani insulin se formuliše kao kokristalizat sa protaminom (insulin izofan suspenzija) ili se humani insulin i brzo-delujući analozi pripremaju kao mešavine insulin izofan suspenzije i monomernog rastvornog oblika u određenim odnosima (75/25, 70/30, 50/50). Kao dugo-delujući insulini primenjuju se analozi insulin glargin i insulin detemir, dok se produženje dejstva stvaranjem amorfne ili kristalne insulin cink suspenzije (lente i ultralente insulin) sve manje koristi, zbog nedovoljno povoljne farmakokinetike. Slično, inhalaciona primena insulina, iako uvedena u kliničku praksu, nije pokazala očekivane prednosti u odnosu na konvencionalnu parenteralnu primenu.
PB  - Savez farmaceutskih udruženja Srbije, Beograd
T2  - Arhiv za farmaciju
T1  - Hormones as biotech-drugs: Human insulin and insulin analogues
T1  - Hormoni kao biotehnološki lekovi - humani insulin i analozi
VL  - 60
IS  - 2
SP  - 207
EP  - 225
UR  - https://hdl.handle.net/21.15107/rcub_farfar_1420
ER  - 
@article{
author = "Savić, Snežana and Vuleta, Gordana and Savić, Miroslav",
year = "2010",
abstract = "Biotech-drugs or biopharmaceuticals are proteins or nucleic acids, which have been produced by living organisms as a result of biotechnology. Three decades after the beginning steps, they make a third part of all new drugs appearing each year at the world market. The era of animal source insulins has passed away and human recombinant DNA insulin and insulin analogues, as biopharmaceutics of the first and second generations, respectively, are the cornerstone of the diabetes mellitus current therapy. All insulin preparations are divided into three groups: 1) short - and rapid-acting insulins; 2) intermediate-acting insulins and 3) long-acting insulins. Short-acting human insulins and rapid-acting analogous insulin lispro, aspart and glulisine are available in form of solution for injections. In order to achieve the intermediate duration of action, human insulin is co-crystallized with protamine (insulin isophane suspensions) or human insulins and rapid-acting analogues are prepared as mixtures of isophane insulin suspension and monomer soluble form in fixed-ratios (75/25, 70/30, 50/50). The currently available long-acting insulins are analogues insulin glargine and insulin detemir, whereas use of amorphous and crystalline insulin zinc suspensions (lente and ultralente insulins) for prolonged action is now very rare, because of insufficiently favorable pharmacokinetics. Similarly, inhalation administration of insulin, although introduced into clinical practice, did not show the expected benefits in comparison to the conventional parenteral use., Biotehnološki lekovi ili biofarmaceutici su proteini ili nukleinske kiseline koje proizvode živi organizmi primenom biotehnoloških postupaka. Tri decenije nakon početnih koraka, oni čine trećinu svih novih lekova koji se svake godine pojave na tržištu u svetu. Era insulina životinjskog porekla je prošla i humani insulin dobijen rekombinantnom DNK tehnologijom i insulinski analozi, kao biotehnološki lekovi prve, odnosno druge generacije, čine osnovu savremene terapije dijabetes melitusa. Svi preparati insulina dele se u tri osnovne grupe: 1) kratko - i brzo-delujuće insuline; 2) srednje-delujuće insuline; 3) dugo-delujuće insuline. Kratko-delujući humani insulin i brzo-delujući analozi insulin lispro, insulin aspart i insulin glulizin prisutni su u obliku rastvora za injekcije. U cilju postizanja srednje dužine dejstva humani insulin se formuliše kao kokristalizat sa protaminom (insulin izofan suspenzija) ili se humani insulin i brzo-delujući analozi pripremaju kao mešavine insulin izofan suspenzije i monomernog rastvornog oblika u određenim odnosima (75/25, 70/30, 50/50). Kao dugo-delujući insulini primenjuju se analozi insulin glargin i insulin detemir, dok se produženje dejstva stvaranjem amorfne ili kristalne insulin cink suspenzije (lente i ultralente insulin) sve manje koristi, zbog nedovoljno povoljne farmakokinetike. Slično, inhalaciona primena insulina, iako uvedena u kliničku praksu, nije pokazala očekivane prednosti u odnosu na konvencionalnu parenteralnu primenu.",
publisher = "Savez farmaceutskih udruženja Srbije, Beograd",
journal = "Arhiv za farmaciju",
title = "Hormones as biotech-drugs: Human insulin and insulin analogues, Hormoni kao biotehnološki lekovi - humani insulin i analozi",
volume = "60",
number = "2",
pages = "207-225",
url = "https://hdl.handle.net/21.15107/rcub_farfar_1420"
}
Savić, S., Vuleta, G.,& Savić, M.. (2010). Hormones as biotech-drugs: Human insulin and insulin analogues. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije, Beograd., 60(2), 207-225.
https://hdl.handle.net/21.15107/rcub_farfar_1420
Savić S, Vuleta G, Savić M. Hormones as biotech-drugs: Human insulin and insulin analogues. in Arhiv za farmaciju. 2010;60(2):207-225.
https://hdl.handle.net/21.15107/rcub_farfar_1420 .
Savić, Snežana, Vuleta, Gordana, Savić, Miroslav, "Hormones as biotech-drugs: Human insulin and insulin analogues" in Arhiv za farmaciju, 60, no. 2 (2010):207-225,
https://hdl.handle.net/21.15107/rcub_farfar_1420 .

Related items

Showing items related by title, author, creator and subject.

  • Low concentration of ammonium decavanadate exhibited insulin mimetic effect on isolated rat adipocytes / Insulin mimetički efekat niskih koncentracija amonijum dekavanadata na izolovane adipocite pacova 

    Topić, Aleksandra; Milenković, Marina; Uskoković-Marković, Snežana; Vučićević, Dragana (Savez farmaceutskih udruženja Srbije, Beograd, 2010)
  • Emerging links between cadmium exposure and insulin resistance: Human, animal, and cell study data 

    Buha, Aleksandra; Đukić-Ćosić, Danijela; Ćurčić, Marijana; Bulat, Zorica; Antonijević, Biljana; Moulis, Jean-Marc; Goumenou, Marina; Wallace, David (MDPI AG, 2020)
  • Influence of obesity on leptin levels and oxidative status in non-insulin dependent diabetes mellitus patients / Uticaj gojaznosti na nivo leptina i oksidativni status kod pacijenata sa diabetes mellitus-om tipa 2 

    Stefanović, Aleksandra; Kotur-Stevuljević, Jelena; Spasić, S.; Bogavac-Stanojević, Nataša; Bujišić, N. (Savez farmaceutskih udruženja Srbije, Beograd, 2006)

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB
 

 

All of DSpaceCommunitiesAuthorsTitlesSubjectsThis institutionAuthorsTitlesSubjects

Statistics

View Usage Statistics

DSpace software copyright © 2002-2015  DuraSpace
About FarFaR - Pharmacy Repository | Send Feedback

OpenAIRERCUB